Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | PDK1 | Q15118 | 9/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3059431 | 0.95 | MEN1 (0.59) | MEN1NPC1KMT2APDK1GAA | |
| SCHEMBL3067593 | 0.89 | MEN1 (0.52) | MEN1NPC1KMT2APDK1GAA | |
| SCHEMBL3057621 | 0.89 | GAA (0.50) | MEN1NPC1KMT2APDK1GAA | |
| SCHEMBL3053493 | 0.88 | PDK1 (0.50) | MEN1NPC1KMT2APDK1GAA | |
| SCHEMBL3065409 | 0.88 | GAA (0.63) | KMT2APDK1GAATSHRPDK2 | |
| SCHEMBL3059962 | 0.86 | GAA (0.54) | PDK1GAATSHRLTB4R2 | |
| SCHEMBL3053488 | 0.85 | MAPK14 (0.54) | MEN1KMT2APDK1GAATSHR | |
| SCHEMBL3057449 | 0.85 | GAA (0.53) | PDK1GAATSHRPDK2PDK4 | |
| SCHEMBL3062368 | 0.83 | GAA (0.64) | PDK1GAATSHR | |
| SCHEMBL3043584 | 0.83 | GAA (0.51) | MEN1KMT2APDK1GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| EP-2001851-A2 | AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREAMENT OF G PROTEIN RELATED DISEASES | Novartis AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007110237-A2 | AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREATMENT OF G PROTEIN RELATED DISEASES | NOVARTIS AG (CH) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | HRH4, CNR1, CNR2 | MEN1 1499/4885NPC1 736/4885KMT2A 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.